 TORONTO, ON ACCESSWIRE December 30, 2020 Edesa Biotech, Inc. NASDAQ:EDSA, a clinical-stage biopharmaceutical company, issued a letter to shareholders from its Chief Executive Officer, Par Nijhawan, providing a review of 2020. Dear Fellow Shareholders, It would be difficult to begin any year-end review without acknowledging the impact that the global health crisis has had on our communities and families, our economy, and on our operations. 